Navigation Links
Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
Date:2/12/2013

KANSAS CITY, Kan. and BOSTON, Mass., Feb. 12, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced it has appointed Don Stitzenberg as Vice President of Manufacturing and Tammy Newbold as Vice President of Chemistry, Manufacturing and Controls. Don and Tammy are both seasoned veterans in the animal health industry and are valuable additions to Aratana's growing team of experts.

Ernst Heinen , DVM, Ph.D., Head of Aratana's Drug Evaluation and Development, stated, "We believe success is contingent on assembling the strongest possible team with proven expertise in all aspects of clinical and commercial drug development. For this reason, we are very pleased to welcome Don and Tammy to Aratana, each of whom are proven experts in establishing and executing quality development and manufacturing programs for animal health drugs."

Donald Stitzenberg
Prior to joining Aratana, Mr. Stitzenberg founded Carnegie Business Associates, an international supply chain consulting company, specializing in the pharmaceutical, chemical and cosmetics industries. He spent 33 years in executive positions at Merck and Co., Inc. in marketing, research, planning and manufacturing. He was Executive Director of Planning for Merck where he led the formation of Merck AgVet, Merck's Animal Health Division. Additionally, he negotiated the formation of Merial Inc., a global animal health joint venture with Rhone Merieux (now Sanofi).

Mr. Stitzenberg holds a BS in mathematics from Carnegie Mellon University where he is a Life Member of the Carnegie Mellon Board of Trustees. He also holds an MBA and an LLB and is a Member of the New Jersey Bar Asso
'/>"/>

SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aratana Therapeutics Completes $15 Million Series B Financing
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
4. Nile Therapeutics Reports 2011 Third Quarter Financial Results
5. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
6. Fate Therapeutics Strengthens Its iPSC Platform
7. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
10. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
11. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Dallas, Texas (PRWEB) August 21, 2014 ... Global Seaweed Fertilizer Industry” is a professional ... Fertilizer market. The report provides basic Seaweed ... application, and industry chain structure as well ... international market analysis, including domestic market as ...
(Date:8/21/2014)... August 21, 2014 The College of ... private college in the Mid-Hudson Region to be designated ... begin accepting applications from qualified “high-technology” businesses that align ... very pleased to have been selected for the START-UP ... transformative initiative to stimulate economic development in New York ...
(Date:8/21/2014)... HONG KONG , Aug. 21, 2014  China Cord ... today announced its plan to release financial results for ... August 28, 2014, after market close in the US.  ... call at 8:00 a.m. ET on Friday, August 29, ... brief overview of the Company,s recent developments, followed by ...
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... HAIFA, Israel, April 14 ES Vascular Ltd. ... approval for its Open Aortic Stapler,(OAS) system for ... repair of AAA and other aortic reconstructions, enabling,commercialization ... on its,proprietary stapling technology, the OAS stapler is ...
... France, April 14 /PRNewswire-FirstCall/,-- Cephalon, Inc. (Nasdaq: ... granted marketing authorization for EFFENTORA(TM), a buccal,tablet formulation ... of,breakthrough cancer pain (BTCP) in adult patients who ... The approval allows Cephalon,to market EFFENTORA in the ...
... HAYWARD, Calif., April 14 Metabolex, Inc., ... development of,proprietary new medicines for the treatment ... Hill has joined the company as chief,financial ... strategic,planning experience to Metabolex, including expertise in ...
Cached Biology Technology:ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease 2Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 2Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 3Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4Metabolex Appoints Donald Hill as Chief Financial Officer 2
(Date:8/22/2014)... be able to purchase fuel cell cars from Toyota ... of the cars will run on hydrogen made from ... warming. , Now scientists at Stanford University have developed ... battery to produce hydrogen by water electrolysis. The ... split liquid water into hydrogen and oxygen gas. Unlike ...
(Date:8/21/2014)... of American singles found that during sex with ... rates. On average, men experience orgasm 85.1 percent ... little difference. For women, however, orgasm occurrence is ... percent of the time during sex with a ... women,s sexual orientation, with lesbian women experiencing orgasm ...
(Date:8/21/2014)... dandruff, eczema and other itchy, flaky maladies in humans ... Hawaiian coral reefs and the extreme environments of arctic ... the scientific journal PLOS Pathogens considers the ... genus Malassezia in light of new insights ... world. , University of Hawai,i at Mānoa scientist Anthony ...
Breaking Biology News(10 mins):Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2
... forms that have been around since the dinosaurs, could ... because they can simultaneously produce other valuable products such ... Engineers at Oregon State University concede that such technology ... science fiction many of the needed advances have ...
...  MedNet Solutions, a global life sciences technology company specializing ... that the latest version of iMedNet ™ ... EDC is a ground-breaking eClinical solution that makes ... type of research initiative...even very small studies of short ...
... press release is available in German . ... Department of Limnology of the University of Vienna unravels the ... the unexpected biogeochemical complexity of dissolved organic matter locked in ... streams. Their paper, now published in Nature Geoscience , ...
Cached Biology News:Ancient diatoms could make biofuels, electronics and health food -- at the same time 2MedNet Solutions Announces Latest Enhancements To Its iMedNet EDC eClinical Solution 2Alpine glaciers contribute to carbon cycling 2
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Mouse Anti-human CD11b/Mac-1alpha, clone LM2/1, Monoclonal Antibody...
Mouse monoclonal [1-N-14] to Adenovirus Type 7 hexon C11 Immunogen: Purified Adenovirus type 7 Specificity: This antibody is specific for Adenovirus type 7 hexon C11....
... Kir2.1 protein. The epitope is specific ... in any other known protein.,SPECIES REACTIVITIES: ... in rabbit, bovine, porcine and guinea ... rat and mouse (17/19 residues) and ...
Biology Products: